Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
Kytopen and Aldevron have announced a joint marketing agreement to enhance cell therapy manufacturing workflows. The collaboration combines Aldevron's Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP platform for CRISPR-mediated T-cell engineering.
Key benefits of this partnership include:
- High transgene expression and improved safety from Nanoplasmid technology
- Gentle gene delivery with unlimited scale through Flowfect continuous flow technology
- Enhanced CRISPR-mediated T-cell engineering with higher yields
- Cost-effective and time-saving manufacturing process
The companies will present their joint findings at the International Society of Cell & Gene Therapy Annual Meeting in New Orleans (May 7-10, 2025). The presentation will showcase increased overall yield of final drug substance and easier manufacturing compared to viral and electroporation technologies.
Kytopen e Aldevron hanno annunciato un accordo di marketing congiunto per migliorare i processi di produzione delle terapie cellulari. La collaborazione unisce la tecnologia vettoriale Nanoplasmid di Aldevron con la piattaforma Flowfect Tx GMP di Kytopen per l'ingegneria delle cellule T mediata da CRISPR.
I principali vantaggi di questa partnership includono:
- Elevata espressione del transgene e maggiore sicurezza grazie alla tecnologia Nanoplasmid
- Consegna genica delicata e scalabilità illimitata tramite la tecnologia a flusso continuo Flowfect
- Ingegneria delle cellule T mediata da CRISPR potenziata con rese più elevate
- Processo di produzione economico e che consente risparmio di tempo
Le aziende presenteranno i risultati congiunti al Meeting Annuale della International Society of Cell & Gene Therapy a New Orleans (7-10 maggio 2025). La presentazione metterà in evidenza un aumento della resa complessiva del principio attivo finale e una produzione più semplice rispetto alle tecnologie virali ed elettroporazione.
Kytopen y Aldevron han anunciado un acuerdo conjunto de marketing para mejorar los procesos de fabricación de terapias celulares. La colaboración combina la tecnología de vectores Nanoplasmid de Aldevron con la plataforma Flowfect Tx GMP de Kytopen para la ingeniería de células T mediada por CRISPR.
Los principales beneficios de esta asociación incluyen:
- Alta expresión del transgén y mayor seguridad gracias a la tecnología Nanoplasmid
- Entrega génica suave con escala ilimitada mediante la tecnología de flujo continuo Flowfect
- Ingeniería de células T mediada por CRISPR mejorada con mayores rendimientos
- Proceso de fabricación rentable y que ahorra tiempo
Las compañías presentarán sus hallazgos conjuntos en la Reunión Anual de la Sociedad Internacional de Terapia Celular y Génica en Nueva Orleans (7-10 de mayo de 2025). La presentación mostrará un aumento en el rendimiento total de la sustancia activa final y una fabricación más sencilla en comparación con las tecnologías virales y de electroporación.
Kytopen과 Aldevron은 세포 치료제 제조 워크플로우를 향상시키기 위한 공동 마케팅 계약을 발표했습니다. 이번 협업은 Aldevron의 Nanoplasmid 벡터 기술과 Kytopen의 Flowfect Tx GMP 플랫폼을 결합하여 CRISPR 기반 T세포 엔지니어링을 지원합니다.
이 파트너십의 주요 이점은 다음과 같습니다:
- Nanoplasmid 기술을 통한 높은 형질전환 유전자 발현 및 안전성 향상
- Flowfect 연속 흐름 기술을 통한 부드러운 유전자 전달과 무한한 확장성
- 향상된 CRISPR 매개 T세포 엔지니어링으로 더 높은 수율 달성
- 비용 효율적이고 시간 절약이 가능한 제조 공정
양사는 2025년 5월 7일부터 10일까지 뉴올리언스에서 열리는 국제 세포 및 유전자 치료 학회 연례 회의에서 공동 연구 결과를 발표할 예정입니다. 발표에서는 바이러스 및 전기천공 기술과 비교하여 최종 약물 물질의 전체 수율 증가와 제조 용이성을 강조할 것입니다.
Kytopen et Aldevron ont annoncé un accord de marketing conjoint visant à améliorer les flux de travail de fabrication des thérapies cellulaires. Cette collaboration associe la technologie de vecteurs Nanoplasmid d'Aldevron à la plateforme Flowfect Tx GMP de Kytopen pour l'ingénierie des cellules T médiée par CRISPR.
Les principaux avantages de ce partenariat sont :
- Expression élevée du transgène et sécurité améliorée grâce à la technologie Nanoplasmid
- Transfert génique doux avec une échelle illimitée grâce à la technologie de flux continu Flowfect
- Ingénierie des cellules T médiée par CRISPR améliorée avec des rendements plus élevés
- Processus de fabrication rentable et gain de temps
Les entreprises présenteront leurs résultats conjoints lors de la Réunion Annuelle de la Société Internationale de Thérapie Cellulaire et Génique à la Nouvelle-Orléans (7-10 mai 2025). La présentation mettra en avant une augmentation du rendement global de la substance médicamenteuse finale et une fabrication facilitée par rapport aux technologies virales et d'électroporation.
Kytopen und Aldevron haben eine gemeinsame Marketingvereinbarung bekannt gegeben, um die Herstellungsabläufe für Zelltherapien zu verbessern. Die Zusammenarbeit kombiniert Aldevrons Nanoplasmid-Vektortechnologie mit Kytopens Flowfect Tx GMP-Plattform für CRISPR-vermittelte T-Zell-Engineering.
Die wichtigsten Vorteile dieser Partnerschaft sind:
- Hohe Transgenexpression und verbesserte Sicherheit durch Nanoplasmid-Technologie
- Schonende Genübertragung mit unbegrenzter Skalierbarkeit durch Flowfect-Kontinuierliche-Fluss-Technologie
- Verbessertes CRISPR-vermitteltes T-Zell-Engineering mit höheren Ausbeuten
- Kosteneffizienter und zeitsparender Herstellungsprozess
Die Unternehmen werden ihre gemeinsamen Ergebnisse auf dem Jahrestreffen der International Society of Cell & Gene Therapy in New Orleans (7.-10. Mai 2025) vorstellen. Die Präsentation zeigt eine erhöhte Gesamtausbeute des Endwirkstoffs und eine einfachere Herstellung im Vergleich zu viralen und Elektroporationstechnologien.
- Joint marketing agreement between Kytopen and Aldevron to enhance cell therapy manufacturing workflow
- Combined technology offers higher edited-cell yields and faster production for CRISPR-based therapies
- Technology integration provides GMP-compliant process ready for clinical and commercial applications
- Partnership addresses growing patient demand in CRISPR therapy market
- No financial terms or revenue projections disclosed
- Early-stage collaboration with unproven commercial success
- Results limited to preliminary data pending presentation at ISCT
Insights
Kytopen-Aldevron partnership combines complementary technologies to streamline CRISPR T-cell engineering, potentially improving manufacturing efficiency without proven commercial impact yet.
This collaboration brings together two complementary technologies for CRISPR-mediated T-cell engineering: Aldevron's Nanoplasmid™ vector technology and Kytopen's Flowfect Tx™ GMP cellular engineering platform. The partnership aims to address persistent manufacturing challenges in cell therapy production through a non-viral approach.
The technical synergy stems from combining Aldevron's high transgene expression capabilities with Kytopen's continuous flow technology for gene delivery. This joint approach claims to deliver higher edited-cell yields with improved efficiency compared to traditional viral and electroporation methods.
From a manufacturing perspective, the emphasis on unlimited scale addresses a critical bottleneck in cell therapy production. Current manufacturing constraints limit patient access to these treatments, making scalable solutions particularly valuable. The companies will present quantitative data at the upcoming ISCT conference that presumably supports their claims of enhanced yields and manufacturing ease.
This joint marketing agreement specifically promotes workflow improvements for cell therapy manufacturers, though it doesn't establish exclusive licensing arrangements. The technology is described as "available for use in clinical and commercial applications," suggesting readiness for GMP implementation, though no current commercial deployments are specified in the release.
Strategic collaboration targets cell therapy manufacturing bottlenecks with promising technology integration, but lacks quantifiable business impact for DHR investors.
This joint marketing agreement represents a strategic positioning move in the competitive cell therapy manufacturing space. By focusing on CRISPR-mediated T-cell engineering, the companies are targeting a high-growth segment where manufacturing inefficiencies remain a significant constraint.
The collaboration claims to deliver a cost-effective approach with higher yields of engineered cells, addressing key economic challenges in cell therapy production. The continuous flow technology approach potentially offers manufacturing advantages that could translate to improved economics, though no specific cost reduction or throughput metrics are provided.
For DHR investors, this partnership expands Aldevron's technology ecosystem in the cell therapy space. However, the announcement provides no financial projections or revenue expectations from this collaboration. As a marketing agreement rather than a commercial contract with committed volumes, the near-term financial impact remains undefined.
The companies' focus on presenting data at the upcoming ISCT conference suggests they are still in the market education and adoption phase rather than widespread commercial implementation. While the press release mentions the technology is "available for use in clinical and commercial applications," it doesn't reference current customers or adoption metrics.
This type of technological collaboration typically represents incremental progress rather than transformative change for large companies like Danaher, though it reinforces their position in the growing cell and gene therapy manufacturing market.
- Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.
- High transgene expression and improved safety profile of Aldveron's Nanoplasmid™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.
- A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in
New Orleans .
Aldveron's Nanoplasmid vector offers high transgene expression and improved safety profile while the Flowfect® continuous flow technology ensures gentle gene delivery with unlimited scale. Together these technologies provide an enhanced CRISPR-mediated T-cell engineering workflow resulting in high yields saving cell therapy developers time in a cost-effective manner.
The two companies created a joint poster of the resulting data that Kypoten will present at the International Society of Cell & Gene Therapy ("ISCT") Annual Meeting, May 7-10, 2025, in
"The work with Aldevron is part of a larger, shared commitment to enable advance cell therapies by streamlining workflows to deliver greater yields of healthier cells," said Kevin Gutshall, Chief Commercial Officer at Kytopen. "The combination of our technologies provides a GMP process for delivering high-quality CAR-T cells that is now available for use in clinical and commercial applications."
"This collaboration continues to demonstrate the superior performance of our Nanoplasmid vectors across novel transfection technologies," said Anu Codaty, VP of Global Marketing and Strategy for Aldevron. "The combination of the Nanoplasmid technology with Kytopen's Flowfect® cell engineering technology has delivered higher edited-cell yields faster, which will help meet the growing patient demand as the adoption of CRISPR-based therapies accelerates."
In addition to the presentations, Kytopen will be available to answer any questions at booth 347 at ISCT.
ISCT Poster Presentation. Wednesday, May 7, 2025, at 6:00pm; POSTER BOARD: 1100
CONTINUOUS FLOW TRANSFECTION WITH FLOWFECT® TECHNOLOGY AS AN EFFICIENT, NON-VIRAL TECHNOLOGY FOR SCALABLE CRISPR-MEDIATED ENGINEERING OF PRIMARY T CELLS
Global Showcase. 15 min Presentation, Thursday, May 8, 2025, at 6:00pm
A FULLY VALIDATED, NON-VIRAL GMP PLATFORM FOR THE MANUFACTURE OF ENGINEERED CELLS AT CLINICAL AND COMMERCIAL SCALE
For further information:
Kytopen:
Investor Contact:
Michael Chiu PhD., CEO
mchiu@kytopen.com
Business and Corporate Development Contact:
Kevin Gutshall, CCO
kgutshall@kytopen.com
Aldevron:
Ellen Shafer, Senior Director of Communications
ellen.shafer@aldevron.com
701-219-0333
About Kytopen:
The innovative leader in non-viral, continuous flow cellular engineering technologies, Kytopen, headquartered in
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/kytopen-and-aldevron-expedite-cell-therapy-manufacturing-through-their-collaborative-crispr-mediated-cellular-engineering-workflow-302441388.html
SOURCE Kytopen
FAQ
What are the benefits of Kytopen and Aldevron's collaboration for cell therapy manufacturing (DHR)?
When will Kytopen present their cell therapy manufacturing data at ISCT 2025?
How does the Flowfect Tx GMP platform improve CAR-T cell production?
What are the key advantages of Aldevron's Nanoplasmid technology for CRISPR therapy?
Where can investors learn more about the Kytopen-Aldevron cell therapy collaboration at ISCT 2025?
